Report : Europe Enteral Medical Nutrition Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]

At 5.9% CAGR, the Europe Enteral Medical Nutrition Market is speculated to be worth US$ 4,042.08 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe enteral medical nutrition market was valued at US$ 2,857.47 million in 2022 and is expected to reach US$ 4,042.08 million by 2028, registering an annual growth rate of 5.9% from 2022 to 2028. Increase in prevalence of cachexia and rise in prevalence of gastrointestinal diseases are the critical factors attributed to the market expansion. 

Cachexia is a multifunctional disease that causes extreme weight loss, skeletal muscle and adipose tissue loss, metabolic regulation imbalance, and food intake reduction. It is a serious clinical consequence of almost all chronic diseases when reaching advanced stages. According to NCBI (National Center for Biotechnology Information), in 2016, cachexia prevalence ranged from 5 to 15% in end-stage chronic heart failure. It is frequently occurring in patients suffering from chronic kidney disease, chronic obstructive pulmonary disease (COPD), neurological disease, and rheumatoid arthritis. Mortality rates of cachexia patients range from 15 to 25% per year in patients with severe COPD and from 20 to 40% per year in patients with chronic heart failure or chronic kidney disease.

Cancer cachexia negatively affects the quality of life of cancer patients and reduces the effectiveness of anticancer chemotherapy and increases its toxicity, leading to growth in cancer-related mortality and medical resources expenditure. In cachexia the nutrient in the body decreases therefore it is necessary to provide external nutrients to continue the treatment for cancer and COPD. Doctors prefer enteral route to provide these required nutrients to the patient. Therefore, growing prevalence of cachexia due to the rising incidence of various chronic diseases fuels the growth of the enteral medical nutrition market.

On the contrary, complications of enteral nutrition hurdle the growth of Europe enteral medical nutrition market.

  • Based on indication, the Europe enteral medical nutrition market is segmented into respiratory disorders, cancer, post COVID-19, gastrointestinal disorders, liver failure, and others. Respiratory disorders held 40.6% market share in 2022, amassing US$ 1,159.85 million. It is projected to garner US$ 1,588.58 million by 2028 to expand at 5.4% CAGR during 2022–2028.
  • Based on nutrition type, the Europe enteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 78.5% market share in 2022, amassing US$ 2,243.79 million. It is projected to garner US$ 3,132.54 million by 2028 to expand at 5.7% CAGR during 2022–2028.
  • Based on form, the Europe enteral medical nutrition market is segmented into powder, liquid, and semi-solid. The semi-solid segment held 48.7% market share in 2022, amassing US$ 1,519.78 million. It is projected to garner US$ 2,185.88 million by 2028 to expand at 6.2% CAGR during 2022–2028.   
  • Based on product, the Europe enteral medical nutrition market is segmented into standard protein diet, high protein diet, fruit juice based oral nutrition, and others. The standard protein diet segment held 52.0% market share in 2022, amassing US$ 1,486.02 million. It is projected to garner US$ 2,067.49 million by 2028 to expand at 5.7% CAGR during 2022–2028.
  • Based on distribution channel, the Europe Enteral Medical Nutrition market is segmented into Hospital Pharmacies, Retail Stores and Other Pharmacies. The Hospital pharmacies segment held 59.5% market share in 2022, amassing US$ 1,699.27 million. It is projected to garner US$ 2,375.96 million by 2028 to expand at 5.7% CAGR during 2022–2028.
  • Based on Age Group, the Europe enteral medical nutrition market is segmented into child (till 18 years) and adults (above 18 years). With 90.2% share of the domain, the adults segment dominated the market in 2022. It accrued US$ 2,576.67 million in 2022 and is estimated to generate US$ 3,615.51 million by 2028 to grow at a CAGR of 5.8% over the forecast period.

Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 841.53 million in 2022 and is likely to hit US$ 1,163.72 million by 2028, exhibiting a CAGR of 5.6% during the forecast period.  

Key players dominating the Europe enteral medical nutrition market are Abbott Laboratories; B. Braun Melsungen AG; DSM Nutritional Products AG; Fresenius Kabi AG; Global Health Products, Inc.; Hormel Foods Corporation; Meiji Holdings Co., Ltd.; Nestlé S.A.; Nutricia; and Smartfish AS among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure